vs
INTERPARFUMS INC（IPAR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是INTERPARFUMS INC的2.0倍（$772.1M vs $386.2M），Revvity净利率更高（12.7% vs 7.3%，领先5.5%），INTERPARFUMS INC同比增速更快（6.8% vs 5.9%），Revvity自由现金流更多（$161.8M vs $145.0M），过去两年INTERPARFUMS INC的营收复合增速更高（9.2% vs 9.0%）
Inter Parfums Inc是全球知名的高端香水企业，开发、生产并销售多款授权香水、身体护理及相关美妆产品，与多家顶级奢侈时尚生活方式品牌合作推出联名香氛系列，产品覆盖全球主要市场，通过百货、美妆专营店及官方电商渠道触达消费者。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
IPAR vs RVTY — 直观对比
营收规模更大
RVTY
是对方的2.0倍
$386.2M
营收增速更快
IPAR
高出1.0%
5.9%
净利率更高
RVTY
高出5.5%
7.3%
自由现金流更多
RVTY
多$16.8M
$145.0M
两年增速更快
IPAR
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.2M | $772.1M |
| 净利润 | $28.1M | $98.4M |
| 毛利率 | 61.5% | — |
| 营业利润率 | 7.1% | 14.5% |
| 净利率 | 7.3% | 12.7% |
| 营收同比 | 6.8% | 5.9% |
| 净利润同比 | 16.0% | 3.9% |
| 每股收益（稀释后） | $0.88 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IPARRVTY
| Q4 25 | $386.2M | $772.1M | ||
| Q3 25 | $429.6M | $698.9M | ||
| Q2 25 | $333.9M | $720.3M | ||
| Q1 25 | $338.8M | $664.8M | ||
| Q4 24 | $361.5M | $729.4M | ||
| Q3 24 | $424.6M | $684.0M | ||
| Q2 24 | $342.2M | $691.7M | ||
| Q1 24 | $324.0M | $649.9M |
净利润IPARRVTY
| Q4 25 | $28.1M | $98.4M | ||
| Q3 25 | $65.8M | $46.7M | ||
| Q2 25 | $32.0M | $53.9M | ||
| Q1 25 | $42.5M | $42.2M | ||
| Q4 24 | $24.2M | $94.6M | ||
| Q3 24 | $62.3M | $94.4M | ||
| Q2 24 | $36.8M | $55.4M | ||
| Q1 24 | $41.0M | $26.0M |
毛利率IPARRVTY
| Q4 25 | 61.5% | — | ||
| Q3 25 | 63.5% | 53.6% | ||
| Q2 25 | 66.2% | 54.5% | ||
| Q1 25 | 63.7% | 56.5% | ||
| Q4 24 | 64.5% | — | ||
| Q3 24 | 63.9% | 56.3% | ||
| Q2 24 | 64.5% | 55.7% | ||
| Q1 24 | 62.5% | 54.6% |
营业利润率IPARRVTY
| Q4 25 | 7.1% | 14.5% | ||
| Q3 25 | 25.3% | 11.7% | ||
| Q2 25 | 17.7% | 12.6% | ||
| Q1 25 | 22.2% | 10.9% | ||
| Q4 24 | 10.0% | 16.3% | ||
| Q3 24 | 25.0% | 14.3% | ||
| Q2 24 | 18.9% | 12.4% | ||
| Q1 24 | 21.0% | 6.8% |
净利率IPARRVTY
| Q4 25 | 7.3% | 12.7% | ||
| Q3 25 | 15.3% | 6.7% | ||
| Q2 25 | 9.6% | 7.5% | ||
| Q1 25 | 12.5% | 6.4% | ||
| Q4 24 | 6.7% | 13.0% | ||
| Q3 24 | 14.7% | 13.8% | ||
| Q2 24 | 10.8% | 8.0% | ||
| Q1 24 | 12.7% | 4.0% |
每股收益（稀释后）IPARRVTY
| Q4 25 | $0.88 | $0.86 | ||
| Q3 25 | $2.05 | $0.40 | ||
| Q2 25 | $0.99 | $0.46 | ||
| Q1 25 | $1.32 | $0.35 | ||
| Q4 24 | $0.78 | $0.77 | ||
| Q3 24 | $1.93 | $0.77 | ||
| Q2 24 | $1.14 | $0.45 | ||
| Q1 24 | $1.27 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $137.1M | $919.9M |
| 总债务越低越好 | $176.0M | — |
| 股东权益账面价值 | $880.7M | $7.3B |
| 总资产 | $1.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资IPARRVTY
| Q4 25 | $137.1M | $919.9M | ||
| Q3 25 | $77.5M | $931.4M | ||
| Q2 25 | $53.9M | $991.8M | ||
| Q1 25 | $75.3M | $1.1B | ||
| Q4 24 | $109.3M | $1.2B | ||
| Q3 24 | $78.8M | $1.2B | ||
| Q2 24 | $37.7M | $2.0B | ||
| Q1 24 | $76.1M | $1.7B |
总债务IPARRVTY
| Q4 25 | $176.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $157.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益IPARRVTY
| Q4 25 | $880.7M | $7.3B | ||
| Q3 25 | $870.9M | $7.4B | ||
| Q2 25 | $839.4M | $7.6B | ||
| Q1 25 | $788.6M | $7.6B | ||
| Q4 24 | $744.9M | $7.7B | ||
| Q3 24 | $778.5M | $7.9B | ||
| Q2 24 | $717.1M | $7.9B | ||
| Q1 24 | $708.1M | $7.8B |
总资产IPARRVTY
| Q4 25 | $1.6B | $12.2B | ||
| Q3 25 | $1.6B | $12.1B | ||
| Q2 25 | $1.6B | $12.4B | ||
| Q1 25 | $1.4B | $12.4B | ||
| Q4 24 | $1.4B | $12.4B | ||
| Q3 24 | $1.5B | $12.8B | ||
| Q2 24 | $1.4B | $13.4B | ||
| Q1 24 | $1.3B | $13.4B |
负债/权益比IPARRVTY
| Q4 25 | 0.20× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $146.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $145.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 37.5% | 21.0% |
| 资本支出强度资本支出/营收 | 0.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 5.21× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $190.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流IPARRVTY
| Q4 25 | $146.5M | $182.0M | ||
| Q3 25 | $63.9M | $138.5M | ||
| Q2 25 | $11.9M | $134.3M | ||
| Q1 25 | $-7.4M | $128.2M | ||
| Q4 24 | $138.0M | $174.2M | ||
| Q3 24 | $76.1M | $147.9M | ||
| Q2 24 | $25.5M | $158.6M | ||
| Q1 24 | $-52.0M | $147.6M |
自由现金流IPARRVTY
| Q4 25 | $145.0M | $161.8M | ||
| Q3 25 | $57.6M | $120.0M | ||
| Q2 25 | $-3.3M | $115.5M | ||
| Q1 25 | $-8.8M | $112.2M | ||
| Q4 24 | $136.1M | $149.8M | ||
| Q3 24 | $75.4M | $125.6M | ||
| Q2 24 | $24.4M | $136.6M | ||
| Q1 24 | $-53.0M | $129.7M |
自由现金流率IPARRVTY
| Q4 25 | 37.5% | 21.0% | ||
| Q3 25 | 13.4% | 17.2% | ||
| Q2 25 | -1.0% | 16.0% | ||
| Q1 25 | -2.6% | 16.9% | ||
| Q4 24 | 37.7% | 20.5% | ||
| Q3 24 | 17.8% | 18.4% | ||
| Q2 24 | 7.1% | 19.7% | ||
| Q1 24 | -16.4% | 20.0% |
资本支出强度IPARRVTY
| Q4 25 | 0.4% | 2.6% | ||
| Q3 25 | 1.5% | 2.6% | ||
| Q2 25 | 4.5% | 2.6% | ||
| Q1 25 | 0.4% | 2.4% | ||
| Q4 24 | 0.5% | 3.4% | ||
| Q3 24 | 0.2% | 3.3% | ||
| Q2 24 | 0.3% | 3.2% | ||
| Q1 24 | 0.3% | 2.7% |
现金转化率IPARRVTY
| Q4 25 | 5.21× | 1.85× | ||
| Q3 25 | 0.97× | 2.97× | ||
| Q2 25 | 0.37× | 2.49× | ||
| Q1 25 | -0.17× | 3.03× | ||
| Q4 24 | 5.69× | 1.84× | ||
| Q3 24 | 1.22× | 1.57× | ||
| Q2 24 | 0.69× | 2.87× | ||
| Q1 24 | -1.27× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IPAR
| European Based Operations | $232.7M | 60% |
| United States Based Operations | $155.2M | 40% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
